![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NT-0796 is an oral, brain-penetrant NLRP3 inflammasome inhibitor, being investigated on inflammation in obese participants at risk of cardiovascular disease.
Lead Product(s): NT-0796
Therapeutic Area: Immunology Product Name: NT-0796
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2024
Details:
NT-0796 is a novel chemotype, designed as an orally bioavailable, brain penetrant NLRP3 inhibitor. NT-0796 has completed its Phase 1 study confirming brain penetration with excellent pharmacokinetic (PK) & pharmacodynamic (PD) profiles.
Lead Product(s): NT-0796
Therapeutic Area: Neurology Product Name: NT-0796
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
Proceeds to support advancement of pipeline of small molecule NLRP3 inflammasome inhibitors, including continued progression of NT-0167 through clinical development.
Lead Product(s): NT-0167
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novo Holdings
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 03, 2020